We are entering a new stage of the severe acute respiratory syndrome coronavirus 2 pandemic with the initiation of large-scale vaccination programs globally. In these circumstances, even rare adverse effects of vaccines may be encountered more often, if millions of people are to be vaccinated in a short period. Vaccination has the potential for causing cutaneous adverse effects. Thus, it is paramount that dermatologists worldwide are acquainted with the possible skin reaction patterns to the coming vaccines. Herein, we conduct a review to discuss the most frequent cutaneous adverse effects of vaccines and their management, with a particular focus on the expected adverse reactions for the coming severe acute respiratory syndrome coronavirus 2 vaccines, such as local reactions, as well as immediate- and delayed-type hypersensitivity reactions, including erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrosis, serum sickness–like reactions, and vasculitides. We also discuss the yet unanswered questions on vaccines for which we may soon be asked to provide an expert opinion.
Get full access to this article
View all access options for this article.
References
1.
KimmelSR.Vaccine adverse events: separating myth from reality. Am Fam Physician, 2002; 66(11):2113–2120.
2.
BadenLR, El SahlyHM, EssinkB, et al.Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med, 2021; 384(5):403–416.
3.
HaagCK, DaceyE, HamiltonN, et al.Aluminum granuloma in a child secondary to DTaP-IPV vaccination: a case report. Pediatr Dermatol, 2019; 36(1):e17–e19.
4.
AvcinS, JazbecJ, JancarJ. Subcutaneous nodule after vaccination with an aluminum-containing vaccine. Acta Dermatovenerol Alp Pannonica Adriat, 2008; 17(4):182–184.
5.
LopesL, FilipeP, AlvesA, et al.Nicolau syndrome after benzathine penicillin treated with hyperbaric oxygen therapy. Int J Dermatol, 2015; 54(4):e103–e106.
6.
SenelE.Nicolau syndrome as an avoidable complication. J Fam Community Med, 2012; 19(1):52–53.
7.
RohEJ, LeeMH, SongKB, et al.Vaccine-related anaphylaxis cases confirmed by KCDC from 2001–2016. J Korean Med Sci, 2020; 35(38):e337.
8.
BohlkeK, DavisRL, MarcySM, et al.Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics, 2003; 112(4):815–820.
9.
McNeilMM, WeintraubES, DuffyJ, et al.Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol, 2016; 137(3):868–878.
10.
RadiceA, CarliG, MacchiaD, et al.Allergic reactions after vaccination: translating guidelines into clinical practice. Eur Ann Allergy Clin Immunol, 2019; 51(2):51–61.
11.
DreskinSC, HalseyNA, KelsoJM, et al.International Consensus (ICON): allergic reactions to vaccines. World Allergy Organ J, 2016; 9(1):1–21.
12.
Palacios CastañoMI, Venturini DíazM, Lobera LabairuT, et al.Anaphylaxis due to the excipient polysorbate 80. J Investig Allergol Clin Immunol, 2016; 26(6):394–396.
StoneCA, LiuY, RellingMV, et al.Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized. J Allergy Clin Immunol Pract, 2019; 7(5):1533–1540.e8.
15.
CalogiuriG, FotiC, NettisE, et al.Polyethylene glycols and polysorbates: two still neglected ingredients causing true IgE-mediated reactions. J Allergy Clin Immunol Pract, 2019; 7(7):2509–2510.
16.
CabanillasB, AkdisC, NovakN.Allergic reactions to the first COVID-19 vaccine: a potential role of polyethylene glycol?Allergy, 2020. doi: 10.1111/all.14711. [Epub ahead of print].
17.
Kleine-TebbeJ, KlimekL, HamelmannE, et al.Severe allergic reactions to the COVID-19 vaccine—statement and practical consequences. Allergol Select, 2021; 5(01):26–28.
18.
GarveyLH, NasserS.Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit?Br J Anaesth, 2021; 126(3):e106–e108.
MatosD, SerranoP, BrandãoFM. Maculopapular rash of unsuspected cause: systemic contact dermatitis to cinchocaine. Cutan Ocul Toxicol, 2015; 34(3):260–261.
22.
WinnickiM, ShearNH. A systematic approach to systemic contact dermatitis and symmetric drug-related intertriginous and flexural exanthema (SDRIFE): a closer look at these conditions and an approach to intertriginous eruptions. Am J Clin Dermatol, 2011; 12(3):171–180.
23.
HäusermannP, HarrT, BircherAJ. Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome?Contact Dermatitis, 2004; 51(5–6):297–310.
24.
CarnicleJM, TranTV, McKissackSS. Systemic contact dermatitis following oral neomycin therapy. Proc (Bayl Univ Med Cent), 2021; 34(1):89–90.
25.
LampelHP, SilvestriDL. Systemic contact dermatitis: current challenges and emerging treatments. Curr Treat Options Allergy, 2014; 1(4):348–357.
RosenblattAE, SteinSL. Cutaneous reactions to vaccinations. Clin Dermatol, 2015; 33(3):327–332.
31.
GuijarroSC, Sánchez-PérezJ, García-DíezA. Allergic contact dermatitis to polyethylene glycol and nitrofurazone. Am J Contact Dermat, 1999; 10(4):226–227.
32.
Antolin-AmerigoD, Sánchez-GonzálezMJ, Barbarroja-EscuderoJ, et al.Allergic reaction to polyethylene glycol in a painter: figure 1. Occup Med (Chic Ill), 2015; 65(6):502–504.
33.
SinghM, WinhovenSM, BeckMH. Contact sensitivity to octyldodecanol and trometamol in an anti-itch cream. Contact Dermatitis, 2007; 56(5):289–290.
BerghM, MagnussonK, NilssonJL, et al.Contact allergenic activity of Tween® 80 before and after air exposure. Contact Dermatitis, 1997; 37(1):9–18.
36.
IsakssonM, JanssonL. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis, 2002; 47(5):312–313.
37.
BhushanM, BeckMH. Allergic contact dermatitis from disodium ethylenediamine tetra-acetic acid (EDTA) in a local anaesthetic. Contact Dermatitis, 1998; 38(3):183.
38.
RussoPA, BanovicT, WieseMD, et al.Systemic allergy to EDTA in local anesthetic and radiocontrast media. J Allergy Clin Immunol Pract, 2014; 2(2):225–229.
39.
Van LaarT, Van HiltenB, NeefC, et al.The role of EDTA in provoking allergic reactions to subcutaneous infusion of apomorphine in patients with Parkinson's disease: a histologic study. Mov Disord, 1998; 13(1):52–55.
40.
YamasujiY, HigashiY, SakanoueM, et al.A case of anaphylaxis caused by polyethylene glycol analogues. Contact Dermatitis, 2013; 69(3):183–185.
41.
WenandeE, KroigaardM, MosbechH, et al.Polyethylene glycols (PEG) and related structures: overlooked allergens in the perioperative setting. A A Case Rep, 2015; 4(5):61–64.
42.
Al-MutairiN, Al-FouzanA, Nour-EldinO. Fixed drug eruption due to influenza vaccine. J Cutan Med Surg, 2004; 8(1):16–18.
43.
ByrdRC, MournighanKJ, Baca-AtlasM, et al.Generalized bullous fixed-drug eruption secondary to the influenza vaccine. JAAD Case Rep, 2018; 4(9):953–955.
44.
SolakB, DikicierBS, KaraRO, et al.DRESS syndrome potentially induced by allopurinol and triggered by influenza vaccine. BMJ Case Rep, 2016; 2016:bcr2016214563.
45.
CalasA, LheureC, BernigaudC, et al.Adenovirus-induced erythema multiforme: eye and genital mucosal involvement is specific, whereas oral and cutaneous involvement is not. Acta Derm Venereol, 2020; 100(13):1–2.
46.
SamimF, AuluckA, ZedC, et al.Erythema multiforme. A review of epidemiology, pathogenesis, clinical features, and treatment. Dent Clin N Am, 2013; 57(4):583–596.
47.
SokumbiO, WetterDA. Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist. Int J Dermatol, 2012; 51(8):889–902.
48.
DemirbaşA, Elmas ÖF, AtasoyM, et al.A case of erythema multiforme major in a patient with COVID 19: the role of corticosteroid treatment. Dermatol Ther, 2020; 33(6):e13899.
49.
GargiuloL, PaviaG, FacherisP, et al.A fatal case of COVID-19 infection presenting with an erythema multiforme–like eruption and fever. Dermatol Ther, 2020; 33(4):e13779.
50.
TorreloA, AndinaD, SantonjaC, et al.Erythema multiforme–like lesions in children and COVID-19. Pediatr Dermatol, 2020; 37(3):442–446.
51.
SuJR, HaberP, NgCS, et al.Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis reported after vaccination, 1999–2017. Vaccine, 2020; 38(7):1746–1752.
52.
MichaelsB.The role of systemic corticosteroid therapy in erythema multiforme major and Stevens-Johnson syndrome: a review of past and current opinions. J Clin Aesthet Dermatol, 2009; 2(3):51–55.
53.
TongJ, ChanJ. Stevens-Johnson syndrome due to influenza vaccination. Cureus, 2020; 12(7):e9405.
54.
BallR, BallLK, WiseRP, et al.Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: reports to the vaccine adverse event reporting system. Pediatr Infect Dis J, 2001; 20(2):219–223.
55.
ChopraA, DrageLA, HansonEM, et al.Stevens-Johnson syndrome after immunization with smallpox, anthrax, and tetanus vaccines. Mayo Clin Proc, 2004; 79(9):1193–1196.
56.
CreamerD, WalshSA, DziewulskiP, et al.UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis 2016. J Plast Reconstr Aesthet Surg, 2016; 69(6):736–741.
EindhovenS, LevelsJ, HuismanM, et al.MPO-ANCA associated vasculitis with mononeuritis multiplex following influenza vaccination. Allergy Asthma Clin Immunol, 2017; 13(1):49.
59.
Melo GomesS, GloverM, MaloneM, et al.Vasculitis following HPV immunization. Rheumatology, 2013; 52(3):581–582.
60.
PiramM, ChiappeSG, MadhiF, et al.Vaccination and risk of childhood IgA vasculitis. Pediatrics, 2018; 142(5):e20180841.
61.
CaoS, SunD. Leucocytoclastic vasculitis following influenza vaccination. BMJ Case Rep, 2017; 2017:bcr2016217755.
62.
WatanabeT.Vasculitis following influenza vaccination: a review of the literature. Curr Rheumatol Rev, 2017; 13(3):188–196.
63.
YungCF, MaX, CheungYB, et al.Kawasaki disease following administration of 13-valent pneumococcal conjugate vaccine in young children. Sci Rep, 2019; 9(1):14705.
64.
PereraK, TimmsH, HeimansJ. New power versus old: to beat antivaccination campaigners we need to learn from them—an essay by Kathryn Perera, Henry Timms, and Jeremy Heimans. BMJ, 2019; 367:l6447.
65.
BeckerRC.COVID-19–associated vasculitis and vasculopathy. J Thromb Thrombolysis, 2020; 50(3):499–511.
66.
ChenKR, CarlsonJA. Clinical approach to cutaneous vasculitis. Am J Clin Dermatol, 2008; 9(2):71–92.
67.
SangolliP, LakshmiD. Vasculitis: a checklist to approach and treatment update for dermatologists. Indian Dermatol Online J, 2019; 10(6):617–626.
68.
ChenWY, HungSJ. Serum sickness–like reaction after diphtheria, tetanus, acellular pertussis, inactivated polio and haemophilus influenzae type B conjugate (5-in-1 vaccine) vaccination: a case report. Dermatol Sin, 2020; 38(2):127–128.
69.
ApisarnthanarakA, UyekiTM, MillerER, et al.Serum sickness–like reaction associated with inactivated influenza vaccination among Thai health care personnel: risk factors and outcomes. Clin Infect Dis, 2009; 49(1):e18–e22.
70.
ChiongFJ, LoewenthalM, BoyleM, et al.Serum sickness-like reaction after influenza vaccination. BMJ Case Rep, 2015; 2015:bcr2015211917.
71.
BaniasadiS, FahimiF, MansouriD. Serum sickness–like reaction associated with cefuroxime and ceftriaxone. Ann Pharmacother, 2007; 41(7–8):1318–1319.
72.
TasanenK, RenkoM, KandelbergP, et al.Childhood lichen planus after simultaneous measles-mumps-rubella and diphtheria-tetanus-pertussis-polio vaccinations. Br J Dermatol, 2008; 158(3):646–648.
73.
JovanovićM, PoljackiM, VujanovićL, et al.Acute febrile neutrophilic dermatosis (Sweet's syndrome) after influenza vaccination. J Am Acad Dermatol, 2005; 52(2):367–369.
MatsuoS, NishizawaA, Oshio-YoshiiA, et al.Influenza vaccine–induced acute generalized exanthematous pustulosis during pregnancy. J Dermatol, 2017; 44(5):598–599.
76.
BaroeroL, CoppoP, BertolinoL, et al.Three case reports of post immunization and post viral bullous pemphigoid: looking for the right trigger. BMC Pediatr, 2017; 17(1):60.
77.
JacksonLA, AndersonEJ, RouphaelNG, et almRNA-1273 StudyGroup. An mRNA vaccine against SARS-CoV-2—preliminary report. N Engl J Med, 2020; 383:1920–1931.
78.
ZhuFC, GuanXH, LiYH, et al.Immunogenicity and safety of a recombinant adenovirus type-5–vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet, 2020; 396(10249):479–488.
79.
BuchbinderSP, McElrathMJ, DieffenbachC, et al.Use of adenovirus type-5 vectored vaccines: a cautionary tale. Lancet, 2020; 396(10260):e68–e69.
